

A European Multinational Cost-effectiveness Analysis of Empagliflozin in Heart Failure with Reduced Ejection Fraction

Ali Tafazzoli (✉ Ali.Tafazzoli@evidera.com)

Evidera Inc <https://orcid.org/0000-0003-1874-1467>

Odette S. Reifsnider

Evidera Inc

Leana Bellanca

Boehringer Ingelheim Ltd

Jack Ishak

Evidera Inc

Marc Carrasco

Boehringer Ingelheim Espana SA Malgrat de Mar

Matthew Stargardter

Evidera Inc

Stephan Linden

Boehringer Ingelheim International GmbH

Research Article

Keywords: Cost-effectiveness, Empagliflozin, Heart failure, Hospitalisation, Reduced ejection fraction, Sodium-glucose cotransporter-2 inhibitor

Posted Date: March 10th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1412156/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Purpose: This research examined the cost-effectiveness of adding empagliflozin to standard of care (SoC) compared with SoC alone for treatment of heart failure with reduced ejection fraction (HFrEF) from the perspective of healthcare payers in the United Kingdom (UK), Spain and France.

Methods: A lifetime Markov cohort model was developed to simulate patients' progression through health states based on Kansas City Cardiomyopathy Questionnaire Clinical Summary Score. The model predicted risk of death, hospitalisation for heart failure (HHF), treatment-related adverse events, and treatment discontinuation each monthly cycle. Clinical inputs and utilities were derived from EMPEROR-Reduced trial data, supplemented by published literature and national costing databases. Costs (2021 pound sterling/euro) and quality-adjusted life years (QALYs) were discounted annually for the UK (3.5%), Spain (3.0%) and France (2.5%).

Results: In the UK, Spain and France, empagliflozin plus SoC yielded additional QALYs (0.19, 0.23 and 0.21) at higher cost (£1,185, €1,770 and €1,183 per patient) than SoC alone, yielding incremental cost-effectiveness ratios of £6,152/QALY, €7,736/QALY and €5,511/QALY, respectively. Reduced HHF incidence provided most cost offsets for empagliflozin plus SoC. Similar results were obtained for a range of subgroups and sensitivity analyses. Probabilistic sensitivity results indicated empagliflozin plus SoC remained cost-effective vs. SoC at willingness-to-pay thresholds of £20,000/QALY, €20,000/QALY and €30,000/QALY in 79.6%, 75.5% and 97.3% of model runs for the UK, Spain and France, respectively.

Conclusions: Empagliflozin added to SoC leads to health benefits for patients with HFrEF and is a cost-effective treatment option for payers in multiple European countries (UK, Spain, France).

Introduction

Heart failure (HF) is characterised by frequent hospitalisations and significantly diminished life expectancy and health-related quality of life (HRQoL), imposing a significant humanistic and economic burden in Europe and internationally [1]. While recent figures are lacking, HF-related expenditures in the European Union were estimated at €29 billion in 2012, driven largely by recurrent and prolonged hospitalisations [2]. European incidence of HF is approximately 5 per 1,000 patient-years (PYs) [3, 4], while recent age-standardised estimates suggest prevalence ranges from 703.8/100,000 people (95% confidence interval [CI]: 609.6, 801.5) in Eastern Europe to 1,058.1/100,000 people (95% CI: 925.5, 1203.5) in Central Europe [5]. HF disproportionately impacts older individuals, and combined with the projected aging of the European population, evidence suggests this burden is likely only to grow in the coming years [6].

HF with reduced ejection fraction (HFrEF; i.e., left ventricular ejection fraction of $\leq 40\%$) comprises approximately half or more of HF cases [4, 7]. As per current European guidelines, the mainstay of treatment for HFrEF is pharmacotherapy, potentially supplemented by device therapy and other interventions which aim to reduce symptoms, improve functional status and HRQoL, and decrease the rate of hospitalisation for worsening heart failure (HHF). Despite these interventions, prognosis for these patients generally remains poor [7].

Recent large-scale clinical trials (DAPA-HF and EMPEROR-Reduced) have shown the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i) (dapagliflozin and empagliflozin) on reducing the risk of cardiovascular (CV) death or HHF in patients with HFrEF [8, 9]. EMPEROR-Reduced compared treatment with empagliflozin (Jardiance[®]) vs. placebo, both in addition to background standard of care (SoC), demonstrating a 25% (hazard ratio [HR]: 0.75; 95% CI: 0.65, 0.86) reduction in the primary composite outcome of CV death or first HHF and 30% (HR: 0.70; 95% CI: 0.58, 0.85) reduction in total HHF [8].

The economic implications of these clinical results are essential to assist healthcare decision-makers in making judicious use of scarce healthcare resources. This research evaluated the cost-effectiveness of adding empagliflozin to SoC compared with SoC alone from the perspective of representative healthcare systems in Europe, namely the United Kingdom (UK), Spain and France.

Methods

Model approach

A Microsoft Excel[®]-based lifetime Markov cohort model with monthly cycles comparing empagliflozin plus SoC vs. SoC alone was developed to simulate patients' progression through health states based on the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS; Fig. 1). The KCCQ score is an established and prognostically important patient-reported measure of health status in HFrEF [10–13]. Scores range from 0 to 100, with higher scores indicating better health status, lower symptom burden and better HRQoL. The clinical severity of HFrEF was modelled by using five health states, based on KCCQ-CSS quartiles, and death.

Several factors motivated the selection of a Markov cohort approach. Such models employ a simple structure and allow for rapid execution of analyses yet possess sufficient flexibility to account for patient heterogeneity through subgroup analyses and can capture both the short- (e.g., episodes of HHF) and long-term impacts of treatment (e.g., disease progression, as reflected in transitions between KCCQ quartiles). This approach also aligns with a recent health economic evaluation of dapagliflozin in HFrEF [14], which concluded that the KCCQ tool was a reasonable measure to classify disease severity and was appropriate for decision-making.

Model description

The modelled cohort was partitioned across the four KCCQ-CSS health states at baseline. Each cycle, patients could remain in the same state, progress to a lower (worse) KCCQ-CSS state, regress to a higher (better) KCCQ-CSS state, or die, and could experience HHF or treatment-related adverse events (AEs) as

transient events while in a KCCQ-CSS state. The model monitored patients' HRQoL and resource use over time as they transitioned between health states and tracked CV- and non-CV-related deaths. Treatment with empagliflozin plus SoC and SoC alone was assumed to impact patient outcomes by influencing the likelihood of transitions between KCCQ-CSS health states, which in turn affected the risk of mortality and HHF and the accrual of both costs and quality-adjusted life years (QALYs). Modelled SoC therapies represented treatments patients in the EMPEROR-Reduced trial received, including diuretics, inhibitors of the renin-angiotensin system and neprilysin, beta-blockers, mineralocorticoid receptor antagonists, and cardiac devices (when indicated). Patients for whom SoC was complemented by empagliflozin gradually discontinued empagliflozin therapy over time, after which they received SoC alone until death or the model horizon expired.

The model structure was the same for the UK, Spain and France, although the inputs used to inform each analysis were country-specific (Supplementary Appendix Section S1). Direct medical costs consisted of expenditures related to drug acquisition, clinical event management, and disease management. Utilities were accrued based on time spent in each KCCQ-CSS state, adjusted for disutilities associated with HHF and AEs. Future costs and benefits were discounted at annual rates of 3.5%, 3.0% and 2.5% for the UK [15], Spain [16] and France [17], respectively. The primary model outcome was the incremental cost-effectiveness ratio (ICER), expressed as cost per QALY gained, measuring the additional cost to gain one QALY by treating patients with empagliflozin plus SoC vs. SoC alone.

Population

The modelled cohort was representative of patients in the EMPEROR-Reduced trial [8]. Patients were initially distributed into KCCQ-CSS quartiles as follows: 0 to < 55 (24.3%), 55 to < 75 (25.1%), 75 to < 90 (27.2%) and 90 to 100 (23.4%). The mean starting age of the cohort was 67 years and 76% were male. Half the patients had history of type 2 diabetes (T2D), 48% had an estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m², and 20% were receiving an angiotensin receptor-neprilysin inhibitor (ARNi) as part of SoC.

The model was equipped to perform a range of pre-specified subgroup analyses based on patient age at baseline (< 65 vs. ≥65 years), presence or absence of T2D, eGFR (< 60 vs. ≥60 mL/min/1.73 m²) and utilisation or non-utilisation of ARNi.

Disease and treatment effect

Disease progression or regression

EMPEROR-Reduced trial data were used to estimate transition probability matrices to capture improvement (ascent) or progression (descent) of disease through KCCQ-CSS quartiles. KCCQ-CSS quartiles were used to ensure enough patient data for robust statistical analysis and sufficient granularity in predicting movement between health states. Treatment-specific monthly transition probabilities between quartiles were computed based on transition count data. Independent transition matrices were developed based on the first three months of follow-up in EMPEROR-Reduced, from month 4 to 8, and from month 9 onward, recognising inflection points observed in the data (Supplementary Appendix Section S3). Transition probabilities were assumed to be equivalent for all patient subgroups.

Treatment discontinuation

Parametric survival analysis of EMPEROR-Reduced trial data was conducted to estimate time to empagliflozin treatment discontinuation (following an exponential distribution), with time-varying KCCQ-CSS as covariates (see Supplementary Appendix for statistical methods [Section S2] and results [Section S3]); alternative distributions were considered in sensitivity analyses. Discontinuation from empagliflozin was assumed to result in similar treatment effect on event risks, costs, and utilities as SoC alone.

Transient-event risks

Risk of first and subsequent HHF was estimated using a Poisson regression model fitted to patient-level EMPEROR-Reduced data with generalised estimating equations to account for the repeated measures on patients (Supplementary Appendix Section S2), including treatment allocation and time-varying KCCQ-CSS health states as covariates (Supplementary Appendix Section S3). Being on treatment with empagliflozin plus SoC or residing in higher KCCQ-CSS quartiles were associated with lower risk of HHF.

The model captured AEs experienced by patients in the EMPEROR-Reduced trial, including urinary tract infection, genital mycotic infection, acute renal failure, hepatic injury, volume depletion, hypotension, hypoglycaemic events and bone fracture. Patients were subject to ongoing risk of experiencing AEs, estimated from the trial data (Supplementary Appendix Section S4). A constant hazard was assumed for each AE.

Mortality

Parametric survival analyses were undertaken using the complete EMPEROR-Reduced dataset to capture all-cause and CV death as a function of treatment and time-varying KCCQ-CSS, both during and beyond the trial duration. Distributions chosen for all-cause and CV death (Weibull) were selected from potential distributions based on goodness of fit and clinical plausibility of long-term projections; alternative distributions were considered in sensitivity analyses. Details regarding the statistical methodology and results of the parametric survival analyses are presented in Supplementary Appendices Sections S2 and S3, respectively.

The risk of non-CV death was assumed to be at least as high as that observed in the population more generally. Accordingly, this was calculated as the difference between the parametric fits for all-cause and CV death, or between rates of age- and sex-specific all-cause mortality predicted from country-specific life tables [18–20] and rates of CV death recorded in national cause-of-death registries [21–23] – whichever was largest.

Utilities

The model applied utility scores ranging from 0 (death) to 1 (full health) to capture the effect of disease severity and clinical events on HRQoL. QALYs accrued during each model cycle, calculated as the difference between KCCQ-CSS health state utilities, and utility decrements attributable to transient events, including HHF and AEs (Table 1; also see Supplementary Appendix Section S5). The impact of transient events on HRQoL was captured as one-off decrements to the proportion of patients experiencing the event and assumed to apply during the month in which those events occurred.

Table 1
Summary of key case-case input parameters

Input parameter	UK	Spain	France
Discount rate: cost	3.5%	3.0%	2.5%
Discount rate: health	3.5%	3.0%	2.5%
Distribution for clinical parameters			
HHF	Poisson	Poisson	Poisson
Time to CV death	Weibull	Weibull	Weibull
Time to all-cause death	Weibull	Weibull	Weibull
Time to empagliflozin treatment discontinuation	Exponential	Exponential	Exponential
Utility parameters			
Health state utility: KCCQ-CSS 0 to 55 (Q1)	0.520	0.629	0.464
Health state utility: KCCQ-CSS 55 to < 75 (Q2)	0.637	0.754	0.610
Health state utility: KCCQ-CSS 75 to < 90 (Q3)	0.710	0.832	0.721
Health state utility: KCCQ-CSS 90 to 100 (Q4)	0.774	0.891	0.810
Disutility: HHF	-0.246	-0.291	-0.240
Disutility: Urinary tract infection	-0.025	-0.025	-0.025
Disutility: Genital mycotic infection	-0.058	-0.053	-0.052
Disutility: Acute renal failure	-0.010	-0.014	-0.011
Disutility: Hepatic injury	-0.016	-0.011	-0.018
Disutility: Volume depletion	-0.018	-0.015	-0.017
Disutility: Hypotension	-0.025	-0.025	-0.025
Disutility: Hypoglycaemic event	-0.048	-0.041	-0.055
Disutility: Bone fracture	-0.165	-0.170	-0.148
Cost parameters			
Monthly drug acquisition cost: empagliflozin + SoC	£79	€157	€129
Monthly drug acquisition cost: SoC	£40	€100	€84
Event management cost: HHF	£3,072	€3,814	€4,968
Event management cost: CV death	£4,146	€6,276	€3,764
Event management cost: Urinary tract infection	£40	€57	€36
Event management cost: Genital mycotic infection	£40	€57	€36
Event management cost: Acute renal failure	£1,906	€4,243	€3,739
Event management cost: Hepatic injury	£1,274	€2,709	€1,055
Event management cost: Volume depletion	£40	€57	€36
Event management cost: Hypotension	£40	€57	€36
Event management cost: Hypoglycaemic event	£627	€1,461	€2,319
Event management cost: Bone fracture	£2,710	€5,042	€3,352
Disease management cost: KCCQ-CSS 0 to 55 (Q1)	£77	€55	€48
Disease management cost: KCCQ-CSS 55 to < 75 (Q2)	£77	€55	€48
Disease management cost: KCCQ-CSS 75 to < 90 (Q3)	£77	€55	€48
Disease management cost: KCCQ-CSS 90 to 100 (Q4)	£77	€55	€48
Abbreviations: CV = cardiovascular; HHF = hospitalisation for worsening heart failure; KCCQ-CSS, Kansas City Cardiomyopathy Questionnaire Clinical Symptom Score; SoC = standard of care; UK = United Kingdom			

EQ-5D-5L responses collected in EMPEROR-Reduced were mapped to EQ-5D-3L using crosswalks formulated by van Hout et al. [24], which were then converted to index scores using published value sets for each of the three countries. Linear mixed-effects regression models (see Supplementary Appendix

Section S3) were constructed to predict utility values from baseline demographics and medical history, time-varying KCCQ-CSS, and clinical events (HHF, AEs).

Utility decrements attributable to HHF were estimated as a weighted average of the relevant coefficients estimated from the regression models, each representing a different duration of time elapsed since the event occurred, and those durations themselves. Disutility estimates for most AEs were sourced directly from the regression model; however, urinary tract infection and hypotension in EMPEROR-Reduced could not be derived from the trial analysis due to low incidence and were obtained from published literature [25, 26].

An age adjustment was applied to KCCQ-CSS health state utility values to account for differences between EMPEROR-Reduced trial and country-specific population norms; in particular, the model assumed HRQoL in KCCQ-CSS quartile 4 would be similar to the population more generally, thereby ensuring utilities for patients in lower quartiles (i.e., whose conditions were more severe) would not be higher than this level.

Costs and resource utilisation

Direct reimbursable medical care costs were expressed in appropriate national currencies (i.e., 2021 British pounds for the UK and 2021 Euros for Spain and France), with adjustments for inflation. The model included costs associated with drug acquisition, management of clinical events, and disease management, sourced from local costing databases and published literature, as appropriate (Table 1).

Drug costs for empagliflozin 10 mg and SoC therapies were extracted from national databases in the three country settings – Monthly Index of Medical Specialties for the UK, BotPlus Web Database in Spain (retail plus value added tax for the base-case analysis and ex-factory price for sensitivity analysis) and the Official Journal in France (public prices including all taxes). For each SoC HF medication class, costs of individual therapies were used to compute an average cost, assuming treatments within each class were uniformly distributed (UK and Spain) or based on local market share (France). Then, the drug cost of SoC was computed as a weighted average cost based on these values and utilisation of HF medication classes at baseline in the empagliflozin plus SoC and SoC arms of EMPEROR-Reduced. Finally, a cost associated with each treatment regimen (i.e., empagliflozin plus SoC and SoC alone) was computed. Indicated strength and dosage for each drug were based on summaries of product characteristics. The cost of empagliflozin 10 mg was incurred until treatment discontinuation, whereas expenditures associated with SoC accrued until death or the model horizon expired.

Expenses for managing clinical events (HHF, CV death and AEs) were obtained from national databases or published literature and modelled as one-off costs. For AEs, these were calculated with reference to the distribution of visit types (i.e., outpatient or inpatient), reflecting their typical severity, and corresponding costs.

HF-related disease management expenditures accrued each cycle and were assumed similar across KCCQ quartiles, reflecting utilisation rates and local costs associated with primary care, cardiologist visits, and accident and emergency referrals. Detailed itemisation of costs incorporated into the model is supplied in Supplementary Appendix Section S6.

Model validation

Validation steps included assessment of face validity, technical validity, predictive validity and cross-validity. Thorough evaluation of face validity and technical validity was supported by an independent modelling expert using the TECHNical VERification checklist (TECH-VER) [27]. Meanwhile, predictive validity was assessed by comparing model-predicted rates of HHF, CV and all-cause death against observed rates from EMPEROR-Reduced (Supplementary Appendix Section S7), while cross-validity entailed identifying and explicating differences in analytical results relative to a recently published model with a similar decision problem [14].

Analyses

The base-case analysis predicted absolute and incremental lifetime cumulative events per 100 PYs, life-years (LY), QALYs and costs with empagliflozin plus SoC vs. SoC alone for the EMPEROR-Reduced trial intent-to-treat (ITT) population. Additionally, the model synthesised results for incremental costs and QALYs to compute the ICER for empagliflozin plus SoC vs. SoC alone. The ICERs for each setting were compared with country-specific, willingness-to-pay (WTP) thresholds – £20,000/QALY for the UK, €20,000/QALY for Spain and €30,000/QALY for France.

Scenarios were run for pre-specified subgroups that were considered clinically and/or economically meaningful (outlined above). Deterministic sensitivity analyses (DSA) were performed using plausible ranges or alternative values for key inputs (i.e., model horizon and discount rates; KCCQ-CSS utilities and utility decrements for AEs and HHF; costs associated with drug acquisition and clinical event/disease management; distributions and treatment effects for clinical outcomes; and whether to exclude treatment discontinuation or the life table adjustment for non-CV mortality) to test the robustness of model results to changes in the parameters. A probabilistic sensitivity analysis (PSA) was conducted using distributions reflecting parameter uncertainties, producing 1,000 pairs of incremental effectiveness and cost estimates. The parameters for sensitivity analyses are provided in Supplementary Appendix Section S8–S9.

Results

Base-case analysis

Empagliflozin plus SoC was associated with fewer HHFs, CV deaths, non-CV deaths and specific AEs (acute renal failure, hepatic injury and hypoglycaemic events) vs. SoC alone in all three country settings over a lifetime horizon (Table 2), consistent with the EMPEROR-Reduced trial results. Due to lower rates of CV and non-CV death, reduced incidence of HHF, and lower disease severity (as reflected in the proportion of time spent in each KCCQ-CSS quartile), patients treated with empagliflozin plus SoC accumulated more discounted LYs (0.18, 0.19 and 0.20 in the UK, Spain and France, respectively), and a larger number of discounted QALYs gained (0.19, 0.23 and 0.21, respectively). Differences in health outcomes reflect the unique demographics of each nation and variation in discount rates applied in the analyses, as well as differences in health technology assessment guidelines.

Table 2
Base-case results estimated over lifetime horizon

	UK (GBP)			Spain (EURO)			France (EURO)		
	Empagliflozin + SoC	SoC	Incremental	Empagliflozin + SoC	SoC	Incremental	Empagliflozin + SoC	SoC	Incremental
Clinical Events, per 100 PY									
HHF	17.60	20.80	-3.20	17.60	20.79	-3.19	17.60	20.79	-3.19
CV death	9.88	10.34	-0.46	9.88	10.34	-0.46	9.89	10.34	-0.46
Non-CV death	4.41	4.46	-0.05	4.36	4.42	-0.05	4.36	4.42	-0.06
Urinary tract infection	3.94	3.76	0.18	3.94	3.76	0.18	3.94	3.76	0.18
Genital mycotic infection	0.95	0.53	0.42	0.95	0.53	0.42	0.95	0.53	0.42
Acute renal failure	8.58	9.02	-0.44	8.58	9.02	-0.44	8.58	9.02	-0.44
Hepatic injury	3.63	3.83	-0.20	3.63	3.83	-0.20	3.63	3.83	-0.20
Volume depletion	9.01	8.76	0.25	9.01	8.76	0.25	9.01	8.76	0.25
Hypotension	7.95	7.69	0.26	7.95	7.69	0.26	7.95	7.69	0.26
Hypoglycaemic event	1.23	1.25	-0.02	1.23	1.25	-0.02	1.23	1.25	-0.02
Bone fracture	1.95	1.89	0.06	1.95	1.89	0.06	1.95	1.89	0.06
Total Cost	£16,661	£15,475	£1,185	€24,319	€22,549	€1,770	€21,726	€20,542	€1,183
Treatment costs	£4,240	£2,673	£1,567	€9,304	€6,950	€2,353	€7,895	€5,947	€1,947
HHF and CV death management costs	£5,418	£5,964	-£546	€7,569	€8,261	-€692	€7,529	€8,392	-€863
AE management costs	£1,615	£1,620	-£5	€3,513	€3,529	-€16	€2,810	€2,824	-€14
Disease management cost	£5,388	£5,219	£169	€3,933	€3,808	€125	€3,492	€3,379	€113
Total LYs	5.81	5.62	0.18	5.96	5.77	0.19	6.11	5.91	0.20
Total QALYs	3.76	3.57	0.19	4.51	4.28	0.23	3.98	3.77	0.21
ICER	-	-	£6,152	-	-	€7,736	-	-	€5,511
Abbreviations: AE = adverse event; CV = cardiovascular; GBP = Great British pound; HHF = hospitalisation for worsening heart failure; ICER = incremental cost-effectiveness ratio; LY = life-years; PY = patient-years; QALY = quality-adjusted life-year; SoC = standard of care; UK = United Kingdom									

As shown in Table 2, empagliflozin plus SoC vs. SoC alone led to additional (discounted) lifetime costs in the UK (£1,185/patient), Spain (€1,770/patient) and France (€1,183/patient), due primarily to higher drug acquisition but partially also to increased disease management costs, which were somewhat offset by savings from clinical events avoided (primarily reduced HHF). Relative to SoC, empagliflozin plus SoC yielded ICERs of £6,152/QALY, €7,736/QALY and €5,511/QALY in the UK, Spain and France, respectively. Considering local WTP thresholds of £20,000/QALY for the UK, €20,000/QALY for Spain and €30,000/QALY for France, these results indicate that empagliflozin plus SoC is cost-effective compared to SoC alone for treatment of patients with HFReF in all three settings.

Sensitivity and subgroup analyses

Empagliflozin plus SoC remained cost-effective compared with SoC alone in DSA considering local WTP thresholds from all three payer perspectives, with ICERs ranging from £4,615–£11,258 in the UK (<£20,000/QALY), €4,073–€13,520 in Spain (<€20,000/QALY) and from €4,123–€11,810 in France (<€30,000/QALY), reinforcing the base-case results. Eliminating the effect of treatment on HHF was the most influential parameter, increasing the ICER in each jurisdiction. That was followed by empagliflozin cost per pack (-20–20%) and discount rate for cost (0–5%, vs. 3.5% in the base-case) in the UK; drug costing source (ex-factory, vs. retail in the base-case) and empagliflozin cost per pack (-20–20%) in Spain; and empagliflozin cost per pack (-20–20%) and discount rate for cost (0–5%, vs. 2.5% in the base-case) in France (Fig. 2; also see Supplementary Appendix Section S8).

The PSA results found that the mean ICERs for the UK, Spain and France were £6,061/QALY, €7,788/QALY and €5,409/QALY, respectively. The chance of empagliflozin plus SoC vs. SoC being cost-effective at WTP thresholds of £20,000/QALY (UK), €20,000/QALY (Spain) and €30,000/QALY (France) were 79.6%, 75.5% and 97.3%, respectively (Fig. 3).

The cost-effectiveness of empagliflozin plus SoC vs. SoC alone was preserved across all subgroups considered in the analysis for each jurisdiction (Table 3). The model predicted empagliflozin plus SoC to be most cost-effective in the subgroup of patients aged < 65 years (UK: ICER of £3,702/QALY; Spain: ICER of

£5,033/QALY; and France: ICER of €2,256/QALY), followed by patients with T2D (UK: ICER of £4,899/QALY; Spain: ICER of €6,405/QALY; and France: ICER of €3,501/QALY).

Table 3
Results of subgroup analyses

ICER-QALY (percent change in ICER from base-case)			
Subgroup	UK	Spain	France
No T2D	£6,996 (14%)	€8,533 (10%)	€6,959 (26%)
T2D	£4,899 (-20%)	€6,405 (-17%)	€3,501 (-36%)
Age < 65 years	£3,702 (-40%)	€5,033 (-35%)	€2,256 (-59%)
Age ≥ 65 years	£7,571 (23%)	€9,205 (19%)	€7,467 (35%)
eGFR < 60 mL/min/1.73m ²	£6,689 (9%)	€8,174 (6%)	€6,806 (24%)
eGFR ≥ 60 mL/min/1.73m ²	£5,581 (-9%)	€7,323 (-5%)	€3,887 (-29%)
Treated with ARNi	£6,305 (2%)	€8,501 (10%)	€7,448 (35%)
Not treated with ARNi	£6,681 (9%)	€8,356 (8%)	€5,480 (-1%)
Abbreviations: ARNi = angiotensin receptor neprilysin inhibitor; eGFR = estimated glomerular filtration rate; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year; T2D = type 2 diabetes; UK = United Kingdom			

Discussion

A lifetime Markov cohort model was developed to assess the cost-effectiveness of empagliflozin plus SoC compared with SoC alone for the treatment of adults with HFrEF in the UK, Spain and France, drawing upon patient-level data from the EMPEROR-Reduced trial. The base-case results demonstrated that empagliflozin plus SoC was highly cost-effective compared with SoC alone. Patients receiving the former experienced lower rates of HHF or CV death compared with the latter, culminating in additional LYs and higher QALYs. Utilising empagliflozin alongside SoC produced higher monthly drug acquisition costs, and greater life expectancy vs. SoC further increased lifetime expenditures for medication, as well as for disease management. These were partially offset by cost-savings from reduced incidence of clinical events, especially HHF, with empagliflozin plus SoC vs. SoC alone. The resultant ICERs fall well below accepted WTP thresholds in each jurisdiction. These findings were broadly supported by results from a series of comprehensive scenario and sensitivity analyses.

The modelling approach adopted in this analysis was consistent with a recently published economic evaluation in HFrEF for the SGLT2i dapagliflozin added to SoC [14]. The dapagliflozin model, however, used the KCCQ-CSS instead of the KCCQ Total Symptom Score (TSS) applied in McEwan et al., 2020. The KCCQ-CSS is a clinically more comprehensive measure than KCCQ-TSS, since it accounts for both the TSS domains (symptom frequency and burden) and physical limitations. Cross-validation of model predictions vs. the dapagliflozin model found higher rates of HHF and CV death with the former. This is as anticipated, given that EMPEROR-Reduced was enriched for higher-risk patients (e.g., reduced ejection fraction and higher levels of natriuretic peptides) compared to DAPA-HF [8].

This model has several strengths. First, it accurately reproduced the EMPEROR-Reduced trial results over the median trial follow-up period of 16 months. Second, disease severity was quantified using the KCCQ-CSS (continuously scaled from 0–100 to assess health status from very poor to excellent), a prognostically important, patient-reported measure of health status which is considered more reliable than physician-reported New York Heart Association (NYHA) classification (places patients into four discrete categories based on physical activity limitations). KCCQ-CSS better captured improvement or progression of disease via transitions of patients between KCCQ-CSS-based health states compared with NYHA classification. Exploratory analyses of EMPEROR-Reduced trial data showed little movement in NYHA health state occupancy (i.e., patients tended to remain in class II/III) over the trial duration. Lastly, non-CV death rates were adjusted using local life tables.

The model was subject to limitations. First, EMPEROR-Reduced collected relatively short-term data, as is typical for a randomised controlled trial. Accordingly, long-term outcomes based on this trial data were extrapolated and are therefore prone to uncertainty. However, sensitivity analyses results imply that the choice of parametric distributions for key clinical outcomes did not significantly impact the estimated ICER, suggesting this residual uncertainty is unlikely to alter the conclusions of the analysis. Additionally, the model did not include diabetic ketoacidosis, a rare complication of SGLT2is. Very few cases of diabetic ketoacidosis were observed in the EMPEROR-Reduced trial, aligned with other results for empagliflozin from the EMPEROR-Preserved trial [28] in HF with preserved ejection fraction and the EMPA-REG OUTCOME trial in patients with T2D and established CV disease. In all trials, very few cases were recorded and no imbalance existed between treatment groups [29].

In conclusion, results of this economic evaluation based on extrapolation of EMPEROR-Reduced trial data demonstrated that compared to SoC alone, empagliflozin added to SoC generates incremental health benefits and represents a cost-effective use of healthcare resources for managing patients with HFrEF from the perspective of payers in the UK, Spain and France.

Declarations

Acknowledgements

The authors gratefully acknowledge Colleen Dumont from Evidera for her editorial assistance, as well as HarinalaGroyer, Marine Bertrand, and Alvaro Lopez from Boehringer Ingelheim and Katia Thokagevistikfor their roles in planning and implementing the analyses and reviewing the manuscript.

Funding

This work was supported by Boehringer Ingelheim International GmbH.

Conflict of Interest

Stephan Linden, Leana Bellanca, and Marc Carrasco are employees of Boehringer Ingelheim. Odette S. Reifsnider, Ali Tafazzoli, Jack Ishak, and Matthew Stargardter are employees of Evidera, a healthcare research firm that provides consulting and other research services to the biopharmaceutical and medical device industry. In these salaried positions, they work with a variety of companies and are explicitly precluded from accepting any payment or honoraria directly from those companies for services rendered. Evidera received payment from Boehringer Ingelheim for collaboration on this project and article.

AuthorContributions

All authors contributed to the model design, analyses, and writing of the manuscript. Model development was performed by AT, OR, and MS. Statistical analyses were conducted by JI, LB, MC, and SL provided support on country specific inputs and assumptions. All authors read and approved the final manuscript.

Data Availability Statement

All data used in this study are informed based on published literature, national costing databases, or patient-level analysis of the EMPEROR-Reduced trial. Our study data (which is based on de-identified data from a clinical trial) is not in a repository, but is available upon reasonable request from the corresponding author.

References

1. Braunschweig F, Cowie MR, Auricchio A. What are the costs of heart failure? *Europace*. 2011 May;**13 Suppl 2**:ii13-17.
2. Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. *Int J Cardiol*. 2014 Feb **15**;**171**(3):368-376.
3. Meyer S, Brouwers FP, Voors AA, Hillege HL, de Boer RA, Gansevoort RT, et al. Sex differences in new-onset heart failure. *Clin Res Cardiol*. 2015 Apr;**104**(4):342-350.
4. Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVENT. *Eur Heart J*. 2013 May;**34**(19):1424-1431.
5. Bragazzi NL, Zhong W, Shu J, Abu Much A, Lotan D, Grupper A, et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. *European Journal of Preventive Cardiology*. 2021.
6. The Heart Failure Policy Network. Heart failure policy and practice in Europe. 2020 [October 27, 2021]; Available from: <https://www.hfpolicynetwork.org/wp-content/uploads/Heart-failure-policy-and-practice-in-Europe.pdf>.
7. Murphy SP, Ibrahim NE, Januzzi JL, Jr. Heart Failure With Reduced Ejection Fraction: A Review. *JAMA*. 2020 Aug **4**;**324**(5):488-504.
8. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *N Engl J Med*. 2020 Oct **8**;**383**(15):1413-1424.
9. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med*. 2019 Nov **21**;**381**(21):1995-2008.
10. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. *J Am Coll Cardiol*. 2000 Apr;**35**(5):1245-1255.
11. Myers J, Zaheer N, Quaglietti S, Madhavan R, Froelicher V, Heidenreich P. Association of functional and health status measures in heart failure. *J Card Fail*. 2006 Aug;**12**(6):439-445.
12. Parissis JT, Nikolaou M, Farmakis D, Paraskevaidis IA, Bistola V, Venetsanou K, et al. Self-assessment of health status is associated with inflammatory activation and predicts long-term outcomes in chronic heart failure. *Eur J Heart Fail*. 2009 Feb;**11**(2):163-169.
13. Sullivan MD, Levy WC, Russo JE, Crane B, Spertus JA. Summary health status measures in advanced heart failure: relationship to clinical variables and outcome. *J Card Fail*. 2007 Sep;**13**(7):560-568.
14. McEwan P, Darlington O, McMurray JJV, Jhund PS, Docherty KF, Bohm M, et al. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. *Eur J Heart Fail*. 2020 Nov;**22**(11):2147-2156.
15. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. 2013 [October 2021]; Available from: <https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781>.
16. Attema AE, Brouwer WBF, Claxton K. Discounting in Economic Evaluations. *Pharmacoeconomics*. 2018 Jul;**36**(7):745-758.
17. Haute Autorité de Santé. Choices in methods for economic evaluation. 2020 [cited 2021 September 1]; Available from: https://www.has-sante.fr/jcms/r_1499251/en/choices-in-methods-for-economic-evaluation.

18. Office for National Statistics. National life tables: UK. 2020 [cited 2021 September 1]; Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreference>
19. Institut National de la Santé et de la Recherche Médicale (INSERM). Causes Médicales de Décès 2021. [cited 2021 June 29]; Available from: <https://cepidc.inserm.fr/causes-medicales-de-deces/interroger-les-donnees-de-mortalite>.
20. Instituto Nacional de Estadística. Tablas de mortalidad por año, sexo, edad y funciones (Unidades: %1000). 2021 [cited 2021 June 29]; Available from: <https://www.ine.es/jaxiT3/dlgExport.htm?t=27153&nocab=1>.
21. Office for National Statistics. Death registrations summary tables - England and Wales. 2018 [cited 2021 September 1]; Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathregistrationssummarytablesendlandandwale>
22. Institut National d'Etudes Démographiques. TABLEAU 68 - TABLE DE MORTALITÉ DES ANNÉES 2017 - 2019, données provisoires arrêtées à fin décembre 2020. 2021 [cited 2021 June 29]; Available from: https://www.ined.fr/fichier/s_rubrique/193/fe_t68_2019.en.xlsx.
23. Instituto Nacional de Estadística. Death according to Cause of Death 2018: Deaths by causes (detailed list), sex and age (National Results; Units: Deaths). 2021 [cited 2021 June 29]; Available from: <https://www.ine.es/jaxi/dlgExport.htm?path=/t15/p417/a2018/11//&file=01000.px&nocab=1&L=1>.
24. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. *Value Health*. 2012 Jul-Aug;**15**(5):708-715.
25. Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. *Med Decis Making*. 2006 Jul-Aug;**26**(4):410-420.
26. Sullivan PW, Ghushchyan VH. EQ-5D Scores for Diabetes-Related Comorbidities. *Value Health*. 2016 Dec;**19**(8):1002-1008.
27. Buyukkaramikli NC, Rutten-van Molken M, Severens JL, Al M. TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility. *Pharmacoeconomics*. 2019 Nov;**37**(11):1391-1408.
28. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. *N Engl J Med*. 2021 Oct 14;**385**(16):1451-1461.
29. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med*. 2015 Nov 26;**373**(22):2117-2128.

Figures




Figure 1

Model diagram

Abbreviations: HF = heart failure; KCCQ-CSS = Kansas City Cardiomyopathy Questionnaire Clinical Summary Score




Figure 2

Deterministic sensitivity analyses (top 10 scenarios)

Abbreviations: CV = cardiovascular; HHF = hospitalisation for heart failure; ICER = incremental cost-effectiveness ratio; KCCQ-CSS = Kansas City Cardiomyopathy Questionnaire Clinical Summary Score; QALY = quality-adjusted life-year; UK = United Kingdom




Figure 3

Incremental cost-effectiveness scatterplots

Abbreviations: QALY = quality-adjusted life-year; UK = United Kingdom

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [EmpaHFrEFCEAMultinationalSupplement01March20221.docx](#)